Study of a targeted antibody-drug therapy for advanced breast cancer
Part of Cancer, Skin clinical trials.
This study tests a new type of targeted therapy called an antibody-drug conjugate (ADC) for advanced breast cancer that is hormone-receptor-positive and HER2-negative. It is for people whose cancer has progressed after CDK4/6 inhibitor treatment, and may offer a new option to slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have advanced breast cancer that is hormone-receptor-positive and HER2-negative (a type that feeds on hormones).
- You have already tried a CDK4/6 inhibitor (like palbociclib) combined with hormone therapy, and your cancer grew despite that treatment.
- You have not had more than 2 lines of chemotherapy for advanced disease.
- You have not been previously treated with a topoisomerase 1 inhibitor (a type of chemotherapy drug).
- You have adequate organ function and can manage daily activities (ECOG score 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with HER2-low breast cancer who have already received two or more antibody-drug conjugates (ADCs) in a row. Researchers want to find the best order to use these targeted therapies to get the most benefit.
This trial is testing the best time to give an antibody-drug conjugate (ADC) to people with advanced breast cancer that is HER2-negative. It aims to find out if giving this treatment after first chemotherapy fails can help slow the cancer's growth.
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
This study is for people with advanced breast, bladder, lung, or stomach cancer who are about to start treatment with a type of targeted therapy called an antibody-drug conjugate (ADC). The trial will collect tumor samples and blood to understand how cancers become resistant to these drugs and to find better ways to predict treatment success.
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
This study tracks how well antibody-drug conjugates (ADCs) work for breast cancer that has spread. You may join if you are about to start your first or second ADC for hormone receptor-positive/HER2-negative or triple-negative breast cancer.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.